AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (NCT05211570)
A Phase 1/2 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Daily Intravenous AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
🩺 Plain-English Summary (8th-Grade Level)
The primary objective is to define the safety and tolerability of AB8939 in patients with AML by determining the dose-limiting toxicities, the maximum tolerated dose, and the recommended dose for dose expansion study.
Who can join: Review the eligibility criteria below.
Location: MD Anderson Cancer Center — Houston, Texas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (10 Sites)
- MD Anderson Cancer Center — Houston, Texas
- Institut Paoli Calmettes — Marseille,
- National and Kapodistrian University of Athens NKUA · Department of Hematology and Bone marrow Transplantation Unit — Athens,
- General University Hospital of Alicantet (Hospital General Universitario Dr. Balmis de Alicante) — Alicante,
- Hospital San Pedro de Alcantara — Cáceres,
- Hospital Universitario 12 de Octubre — Madrid,
- Hospital Universitario Quirónsalud — Madrid,
- MD Anderson Cancer Center Madrid — Madrid,
- Clínica Universidad de Navarra — Pamplona,
- Virgen del Rocío University Hospital (Hospital Universitario Virgen del Rocío) — Seville,
📞 Contact the Study Coordinator
Phone: +33(0)147200014
Email: clinical@ab-science.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Myeloid Leukemia Refractory
- A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia — Basking Ridge, New Jersey
Explore by condition: All Acute Myeloid Leukemia Refractory clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.